Generic name: Selumetinib
Dosage form: Capsule
Drug class: Multikinase inhibitors

What is Koselugo?

Koselugo is a targeted therapy developed by AstraZeneca and licensed from Array BioPharma (a subsidiary of Pfizer). It is the first FDA-approved treatment specifically for NF1-related plexiform neurofibromas.